Monopar Therapeutics, Inc. (MNPR)
70.65
-1.93
(-2.66%)
USD |
NASDAQ |
Oct 23, 16:00
71.89
+1.24
(+1.76%)
After-Hours: 20:00
Monopar Therapeutics Enterprise Value : 340.03M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 340.03M |
| October 22, 2026 | 352.98M |
| October 21, 2026 | 351.44M |
| October 20, 2026 | 364.06M |
| October 19, 2026 | 345.53M |
| October 16, 2026 | 330.76M |
| October 15, 2026 | 347.74M |
| October 14, 2026 | 356.47M |
| October 13, 2026 | 349.62M |
| October 12, 2026 | 382.98M |
| October 09, 2026 | 395.80M |
| October 08, 2026 | 429.50M |
| October 07, 2026 | 428.16M |
| October 06, 2026 | 399.90M |
| October 05, 2026 | 391.31M |
| October 02, 2026 | 389.16M |
| October 01, 2026 | 389.16M |
| September 30, 2026 | 400.57M |
| September 29, 2026 | 402.78M |
| September 28, 2026 | 427.75M |
| September 25, 2026 | 437.92M |
| September 24, 2026 | 462.12M |
| September 23, 2026 | 465.75M |
| September 22, 2026 | 514.41M |
| September 21, 2026 | 508.30M |
| Date | Value |
|---|---|
| September 18, 2026 | 513.33M |
| September 17, 2026 | 555.15M |
| September 16, 2026 | 546.76M |
| September 15, 2026 | 566.09M |
| September 14, 2026 | 592.87M |
| September 11, 2026 | 605.90M |
| September 10, 2026 | 603.88M |
| September 09, 2026 | 620.13M |
| September 08, 2026 | 633.55M |
| September 04, 2026 | 654.90M |
| September 03, 2026 | 661.54M |
| September 02, 2026 | 646.30M |
| September 01, 2026 | 654.96M |
| August 31, 2026 | 617.11M |
| August 28, 2026 | 616.84M |
| August 27, 2026 | 630.60M |
| August 26, 2026 | 629.12M |
| August 25, 2026 | 609.65M |
| August 24, 2026 | 613.28M |
| August 21, 2026 | 588.85M |
| August 20, 2026 | 610.06M |
| August 19, 2026 | 697.05M |
| August 18, 2026 | 664.90M |
| August 17, 2026 | 647.71M |
| August 14, 2026 | 624.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 534.42M |
| Amgen, Inc. | 280.78B |
| Anika Therapeutics, Inc. | 273.50M |
| BioCryst Pharmaceuticals, Inc. | 2.436B |
| Imunon, Inc. | 6.743M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.313M |
| Total Expenses (Quarterly) | 5.313M |
| EPS Diluted (Quarterly) | -0.622 |
| Earnings Yield | -3.31% |
| Normalized Earnings Yield | -3.309 |